Fingerprint
Dive into the research topics where Lea Baer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
ICON: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined...
Andrzejczyk, A. (CoI), Baer, L. (CoI), Cohen, J. (CoI) & Stopeck, A. (CoI)
02/27/26 → 10/3/26
Project: Research
-
MonarchE: A Randomized Open-Label Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive
Baer, L. (CoI), Cohen, J. (CoI) & Stopeck, A. (CoI)
11/7/17 → 07/31/26
Project: Research
-
Nektar Therapeutics: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated...
Baer, L. (PI), Cohen, J. (CoPI), Stopeck, A. (CoPI) & Kudelka, A. (CoPI)
12/7/17 → 07/19/18
Project: Research
-
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >1 CM Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...
Cohen, J. (PI), Baer, L. (CoPI) & Stopeck, A. (CoPI)
09/26/17 → 06/30/22
Project: Research
-
A Phase 1b open label study to evaluate the safety and efficacy of MPDL3280A in combination with talimogene laherparepvec in patients with triple negative breast cancer and in patients with colorectal cancer with liver metastases...
Cohen, J. (PI), Baer, L. (CoPI), Stopeck, A. (CoPI), Zhang, Y. (PI) & Choi, M. (CoPI)
09/6/17 → 02/22/22
Project: Research
-
Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study
Gemmill, J. A. L., Thompson, P., Batiste, R., Vacchi-Suzzi, C., Preece, C., Cohen, J., Baer, L., Mies, C., Turner, M., Russell, C. A. & Stopeck, A., Jul 2025, In: Breast Cancer Research and Treatment. 212, 2, p. 407-413 7 p.Research output: Contribution to journal › Article › peer-review
-
Utility of Stereotactic Body Radiation Therapy in Establishing Local Control for Patients With Invasive Breast Cancer Not Undergoing Definitive Surgery
Zabrocka, E., Polce, S., Roberson, J. D., Wu, J., Cohen, J., Baer, L., Stopeck, A., Ryu, S. & Stessin, A., Feb 1 2024, In: International Journal of Radiation Oncology, Biology, Physics. 118, 2, p. 436-442 7 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations -
Biomarkers and Strain Echocardiography for the Detection of Subclinical Cardiotoxicity in Breast Cancer Patients Receiving Anthracyclines
Bhagat, A. A., Kalogeropoulos, A. P., Baer, L., Lacey, M., Kort, S., Skopicki, H. A., Butler, J. & Bloom, M. W., Dec 2023, In: Journal of Personalized Medicine. 13, 12, 1710.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations -
Randomized Phase II Trial of Endocrine Therapy with or Without Ribociclib after Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptora-Positive, Human Epidermal Growth Factor Receptor 2a-Negative Metastatic Breast Cancer: MAINTAIN Trial
Kalinsky, K., Accordino, M. K., Chiuzan, C., Mundi, P. S., Sakach, E., Sathe, C., Ahn, H., Trivedi, M. S., Novik, Y., Tiersten, A., Raptis, G., Baer, L. N., Oh, S. Y., Zelnak, A. B., Wisinski, K. B., Andreopoulou, E., Gradishar, W. J., Stringer-Reasor, E., Reid, S. A. & O'Dea, A. & 3 others, , Aug 20 2023, In: Journal of Clinical Oncology. 41, 24, p. 4004-4013 10 p.Research output: Contribution to journal › Article › peer-review
151 Scopus citations -
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
Kalinsky, K., Accordino, M. K., Chiuzan, C., Mundi, P. S., Trivedi, M. S., Novik, Y., Tiersten, A., Raptis, G., Baer, L. N., Young Oh, S., Zelnak, A. B., Wisinski, K. B., Andreopoulou, E., Gradishar, W. J., Stringer-Reasor, E., Reid, S. A., O'Dea, A., O'Regan, R., Crew, K. D. & Hershman, D. L., Jun 10 2022, In: Journal of Clinical Oncology. 40, p. LBA1004-LBA1004Research output: Contribution to journal › Article › peer-review
1 Scopus citations